Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Trypanosoma cruzi | trypanothione reductase, putative | Curated by TDR Targets | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | trypanothione reductase, putative | 492 aa | 548 aa | 21.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | protein farnesyltransferase beta subunit | 0.0111 | 0.3551 | 0.8661 |
Giardia lamblia | Prenyltransferase | 0.0111 | 0.3551 | 1 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Toxoplasma gondii | prenyltransferase and squalene oxidase repeat-containing protein | 0.0111 | 0.3551 | 1 |
Trichomonas vaginalis | geranylgeranyl transferase type I beta subunit, putative | 0.0111 | 0.3551 | 1 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit/RAB geranylgeranyl transferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Schistosoma mansoni | dopamine-beta-monooxygenase | 0.0127 | 0.4359 | 0.4334 |
Schistosoma mansoni | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Plasmodium vivax | conserved Plasmodium protein, unknown function | 0.0081 | 0.2037 | 0.5683 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0076 | 0.1787 | 0.4971 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Leishmania major | lanosterol synthase, putative | 0.0092 | 0.2579 | 0.7229 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0122 | 0.4094 | 1 |
Trypanosoma cruzi | protein farnesyltransferase, putative | 0.0111 | 0.3551 | 0.8661 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0065 | 0.1212 | 0.1173 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0076 | 0.1787 | 0.4971 |
Trichomonas vaginalis | geranylgeranyl transferase type beta subunit, putative | 0.0111 | 0.3551 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0076 | 0.1787 | 0.1751 |
Trypanosoma cruzi | lanosterol synthase, putative | 0.0122 | 0.4094 | 1 |
Trypanosoma cruzi | protein farnesyltransferase, putative | 0.0111 | 0.3551 | 0.8661 |
Plasmodium falciparum | glutathione reductase | 0.0076 | 0.1787 | 0.4971 |
Loa Loa (eye worm) | prenyltransferase and squalene oxidase repeat family protein | 0.0111 | 0.3551 | 0.3523 |
Mycobacterium tuberculosis | Halimadienyl diphosphate synthase | 0.0122 | 0.4094 | 1 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0076 | 0.1787 | 0.4305 |
Toxoplasma gondii | thioredoxin reductase | 0.0076 | 0.1787 | 0.4971 |
Loa Loa (eye worm) | glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Schistosoma mansoni | peptidylglycine monooxygenase | 0.0127 | 0.4359 | 0.4334 |
Brugia malayi | glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Echinococcus multilocularis | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Trypanosoma brucei | trypanothione reductase | 0.0076 | 0.1787 | 0.4305 |
Trichomonas vaginalis | protein farnesyltransferase alpha subunit, putative | 0.0041 | 0.0044 | 0.0123 |
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.024 | 1 | 1 |
Leishmania major | trypanothione reductase | 0.0076 | 0.1787 | 0.4971 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Trichomonas vaginalis | type I geranylgeranyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0076 | 0.1787 | 0.4971 |
Trichomonas vaginalis | geranylgeranyl transferase type II beta subunit, putative | 0.0111 | 0.3551 | 1 |
Plasmodium falciparum | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0076 | 0.1787 | 0.1751 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.024 | 1 | 1 |
Leishmania major | farnesyltransferase beta subunit | 0.0111 | 0.3551 | 1 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.024 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.4359 | 0.4334 |
Onchocerca volvulus | 0.0041 | 0.0044 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.024 | 1 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0127 | 0.4359 | 0.4334 |
Plasmodium vivax | farnesyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0076 | 0.1787 | 0.1751 |
Brugia malayi | Prenyltransferase and squalene oxidase repeat family protein | 0.0111 | 0.3551 | 0.3523 |
Entamoeba histolytica | protein farnesyltransferase beta subunit, putative | 0.0111 | 0.3551 | 1 |
Trypanosoma brucei | lanosterol synthase | 0.0122 | 0.4094 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0063 | 0.1116 | 0.1077 |
Echinococcus granulosus | protein farnesyltransferase subunit beta | 0.0111 | 0.3551 | 0.3523 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 24.7 uM | Cytotoxicity against BALB/c mouse spleen cells | ChEMBL. | 17081761 |
IC50 (functional) | = 3.96 uM | Inhibition of LPS-induced BALB/c mouse B cell proliferation | ChEMBL. | 17081761 |
IC50 (functional) | = 10 uM | Inhibition of ConA-induced BALB/c mouse T cell proliferation | ChEMBL. | 17081761 |
Ratio CC50/IC50 (functional) | = 2 | Selectivity index, ratio of CC50 for BALB/c mouse spleen cells to IC50 for BALB/c mouse T cells | ChEMBL. | 17081761 |
Ratio CC50/IC50 (functional) | = 6 | Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for BALB/c mouse B cells | ChEMBL. | 17081761 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.